Browse All

Current Filters

CLEAR FILTER x

TITLE

Pridopidine for the Treatment of ALS—Results from the Phase 2 Healey ALS Platform Trial

Author:Shefner, Jeremy   Oskarsson, Bjorn   Cohen, Yael   Chen, Kelly   Leitner, Melanie   Berry, James   Macklin, Eric   Chibnik, Lori   Pothier, Lindsay   Geva, Michal   Goldberg, Paul   Hayden, Michael   Paganoni, Sabrina   Cudkowicz, Merit   

Session Name:S5: ALS and CMT: New Therapeutic Approaches  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S5.003  

Author Institution:Barrow Neurological Institute, Phoenix, AZ  Mayo Clinic, Jacksonville, FL  Prilenia Therapeutics, Kibbutz Yakum, Israel  Accelerating NeuroVentures, LLC, Needham, MA  Massachusetts General Hospital, Boston, MA  Prilenia Therapeutics, Herzlyia, Israel  

Results from a Phase 2 Clinical Trial of Repeated Intrathecal Autologous Adipose-derived MSCs in ALS

Author:Staff, Nathan   Oskarsson, Bjorn   Muzyka, Iryna   Madigan, Nicolas   Mester, Carly   Figdore, Daniel   Turner, Michelle   Thuro, Lisa   Osgood, Thomas   Madde, Pranathi   Deeds, Michael   Wiltshire, Timothy   Algeciras-Schimnich, Alicia   Mandrekar, Jayawant   Dietz, Allan   Windebank, Anthony   

Session Name:S5: ALS and CMT: New Therapeutic Approaches  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S5.004  

Author Institution:Mayo Clinic, Rochester, MN  Mayo Clinic Florida, Jacksonville, FL  Mayo Clinic Arizona, Scottsdale, AZ  

Value of FVC and its Rate of Decline for Predicting Survival in ALS

Author:Seyam, Muhannad   Hubbell, Richard   Howard, Diantha   Skelly, Joan   Waheed, Waqar   Tandan, Rup   

Session Name:S5: ALS and CMT: New Therapeutic Approaches  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S5.005  

Author Institution:University of Vermont Medical Center, Burlington, VT  University of Vermont, Burlington, VT  

Next Generation Prodrug Troriluzole: Increased Bioavailability of Riluzole with No Food Effect in Healthy Subjects

Author:Sevinsky, Heather   Rozakis, Rachel   Nepomuceno, Tracy   Malatesta, Jo Ann   Awsare, Bharat   Ashbrenner, Eric   Kaplita, Stephen   Gentile, Kimberly   Hussey, Elizabeth   Qureshi, Irfan   Coric, Vladimir   Bertz, Richard   

Session Name:S5: ALS and CMT: New Therapeutic Approaches  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S5.006  

Author Institution:Biohaven Pharmaceuticals, Inc, New Haven , CT  Allucent, Cary, NC  Biohaven Pharmaceuticals, Inc, New Haven, CT  Certara, Inc, Princeton, NJ  Biohaven Pharmaceuticals, Inc, New Haven, CT  Biohaven Pharmaceuticals, Inc, Cheshire, CT  

Inhibition of MicroRNA-183 Attenuates Pathological TDP-43 Aggregation via SQSTM1/p62 in ALS

Author:Lu, Liang   Kim, Han-Cheon   Zhang, Yan   King, Peter   

Session Name:S5: ALS and CMT: New Therapeutic Approaches  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S5.007  

Author Institution:BCM, BELLAIRE, TX  UTH, Houston, TX  BCM, Houston, TX  UAB, Birmingham, AL